

Supplementary Material

Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

Gerald Chi, M.D.¹; Jane J. Lee, Ph.D.²; Adeel Jamil, M.D.³; Vamsikrishna Gunnam, M.D.¹; Homa Najafi, M.D.¹;
Sahar Memar Montazerin, M.D.¹; Fahimehalsadat Shojaei, M.D.¹; Jolanta Marszalek, M.D.⁴

¹ Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

² Baim Institute for Clinical Research, Boston, MA, United States

³ Department of Medicine, OSF Saint Francis Medical Center, Peoria, IL, United States

⁴ Department of Neurology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA, United States

Table of Contents

Table S1. Search strategy

Table S2. Quality assessment criteria for cohort studies

Table S3. Quality assessment form for cohort studies

Table S4. Summary of Egger's test for small-study effect

Figure S1. PRISMA flow diagram

Figure S2. Funnel plot of VTE

Figure S3. Funnel plot of PE

Figure S4. Funnel plot of DVT

Figure S5. Rate of mortality among COVID-19 patients undergoing thromboprophylaxis

Figure S6. Funnel plot of mortality

Figure S7. Mean difference in D-dimer between cases and controls

Figure S8. Summary of VTE incidence by clinical setting

Supplementary Material

Table S1. Search strategy

Query in PubMed
((coronavirus or corona-virus) AND (2019-nCoV or nCoV or COVID-19 or Covid19 or SARS-CoV* or SARSCov2 or ncov)) OR (pneumonia AND Wuhan) or "COVID-19" or "2019-nCoV" or "SARS-CoV" or SARSCOV2 or 2019-nCov or "2019 coronavirus" or "2019 corona virus" or covid19 or ncov OR "novel corona virus" or "new corona virus" or "2019 corona virus" OR "novel coronavirus" or "new coronavirus" or "2019 coronavirus") AND (deep vein thrombosis OR pulmonary embolism OR venous thromb*) AND (thromboprophylaxis OR prophylaxis OR prevention OR anticoagula* OR heparin OR enoxaparin OR bemiparin OR nadroparin OR reviparin OR parnaparin OR certoparin OR dalteparin OR tinzaparin) AND English [lang]

Supplementary Material

Table S2. Quality assessment criteria for cohort studies

Domain	Item	Criterion	Rating
Selection	Representativeness of the Exposed Cohort (0 to 1)	Exposed individuals are representative in the community.	1
		No description.	0
	Selection of the Non-Exposed Cohort (0 to 1)	Drawn from the same community as the exposed cohort.	1
		No description.	0
	Ascertainment of Exposure (0 to 1)	Secure records (e.g. medical records/research records).	1
		No description.	0
	Demonstration That Outcome of Interest Was Not Present at Start of Study (0 to 1)	Yes	1
		No description.	0
Comparability	Matched or Adjusted by Key Factors (0 to 1)	Reported VTE risk factors.	1
	Matched or Adjusted by Additional Factors (0 to 1)	Reported D-dimer levels.	1
Outcome	Assessment of Outcome (0 to 1)	Independent or blind assessment, confirmation of the outcome by reference to secure records (e.g. medical records/research records), or record linkage (e.g. identified through ICD codes on database records).	1
		Self-reported records only, or not stated.	0
	Was Follow-Up Long Enough for Outcomes to Occur (0 to 1)	Yes (at least one week).	1
		Less than one week or no description.	0
	Adequacy of Follow Up of Cohorts (0 to 1)	At least 80% of subjects complete the follow-up, and subjects lost to follow-up are unlikely to introduce bias.	1
		Follow up rate < 80% and no description of subjects lost to follow-up.	0


Supplementary Material

Table S4. Summary of Egger's test for small-study effect

Endpoint	z	P-value
VTE	-0.1343	0.8932
PE	-1.8676	0.0618
DVT	-3.2302	0.0012
Mortality	-1.3295	0.1837


Supplementary Material

Figure S1. PRISMA flow diagram




Supplementary Material

Figure S2. Funnel plot of VTE




Supplementary Material

Figure S3. Funnel plot of PE




Supplementary Material

Figure S4. Funnel plot of DVT




Supplementary Material

Figure S5. Rate of mortality among COVID-19 patients undergoing thromboprophylaxis




Supplementary Material

Figure S6. Funnel plot of mortality



Supplementary Material

Figure S7. Mean difference in D-dimer between cases and controls



Supplementary Material

Figure S8. Summary of VTE incidence by clinical setting

